CoChat
Sign Up
Cited by 139

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial

Ho, Carolyn Y., Day, Sharlene M., Axelsson, Anna, Russell, Mark W., Zahka, Kenneth, Lever, Harry M., Pereira, Alexandre C., Colan, Steven D., Margossian, Renee, Murphy, Anne M., Canter, Charles, Bach, Richard G., Wheeler, Matthew T., Rossano, Joseph W., Owens, Anjali T., Bundgaard, Henning, Benson, Lee, Mestroni, Luisa, Taylor, Matthew R. G., Patel, Amit R., Wilmot, Ivan, Thrush, Philip, Vargas, Jose D., Soslow, Jonathan H., Becker, Jason R., Seidman, Christine E., Lakdawala, Neal K., Cirino, Allison L., VANISH Investigators, Krieger, Jose E., Sacilotto, Luciana, Arteaga, Edmundo, Antunes, Murilo O., Hall, E. Kevin, Choudhury, Lubna, Pahl, Elfriede, Lin, Kimberly Y., Lewis, Gregory D., Desai, Akshay S., Burns, Kristin M., McMurray, John J. V., MacRae, Calum A., Solomon, Scott D., Orav, E. John, Braunwald, Eugene·2021·Nature Medicine
DOI 10.1038/s41591-021-01505-4PMC PMC8666141
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01505-4

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 22

  1. Writing Committee M. et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142, e558–e631 (2020).
  2. Seidman, C. E. & Seidman, J. G. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ. Res. 108, 743–750 (2011). · DOI · Paper page
  3. Ho, C. Y. et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138, 1387–1398 (2018). · DOI · Paper page
  4. Kim, J. B. et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 316, 1481–1484 (2007). · DOI
  5. Lopez, B., Gonzalez, A. & Diez, J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 121, 1645–1654 (2010). · DOI
  6. Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J. Clin. Invest. 120, 3520–3529 (2010). · DOI
  7. Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117–121 (2006). · DOI · Paper page
  8. Kawano, H. et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ. J. 69, 1244–1248 (2005). · DOI
  9. Araujo, A. Q. et al. Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 96, 1563–1567 (2005). · DOI
  10. Yamazaki, T. et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int. Heart J. 48, 715–724 (2007). · DOI
  11. Penicka, M. et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J. Mol. Diagn. 11, 35–41 (2009). · DOI
  12. Shimada, Y. J. et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 1, 480–487 (2013). · DOI
  13. Axelsson, A. et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 3, 123–131 (2015). · DOI
  14. Ho, C. Y. et al. The design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial. Am. Heart J. 187, 145–155 (2017). · DOI
  15. Axelsson Raja, A. et al. Baseline characteristics of the VANISH cohort. Circ. Heart Fail. 12, e006231 (2019). · DOI
  16. Sun, H., Davison, B. A., Cotter, G., Pencina, M. J. & Koch, G. G. Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method. Circ. Heart Fail. 5, 742–749 (2012). · DOI
  17. Semsarian, C. et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109, 1013–1020 (2002). · DOI
  18. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862–D868 (2016). · DOI · Paper page
  19. Ho, C. Y. et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ. Cardiovasc. Genet. 2, 314–321 (2009). · DOI
  20. Ho, C. Y. et al. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart 102, 1805–1812 (2016). · DOI
  21. Ho, C. Y. et al. The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: findings from the HCMNet study. JAMA Cardiol. 2, 419–428 (2017). · DOI
  22. Ho, C. Y. et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 3, 180–188 (2015). · DOI

Cited by

Sorted by citations

See all 139

Metadata

Authors
Ho, C. Y., Day, S. M., Axelsson, A., Russell, M. W., Zahka, K., Lever, H. M., Pereira, A. C., Colan, S. D., Margossian, R., Murphy, A. M., Canter, C., Bach, R. G., Wheeler, M. T., Rossano, J. W., Owens, A. T., Bundgaard, H., Benson, L., Mestroni, L., Taylor, M. R. G., Patel, A. R., Wilmot, I., Thrush, P., Vargas, J. D., Soslow, J. H., Becker, J. R., Seidman, C. E., Lakdawala, N. K., Cirino, A. L., VANISH Investigators, Krieger, J. E., Sacilotto, L., Arteaga, E., Antunes, M. O., Hall, E. K., Choudhury, L., Pahl, E., Lin, K. Y., Lewis, G. D., Desai, A. S., Burns, K. M., McMurray, J. J. V., MacRae, C. A., Solomon, S. D., Orav, E. J., & Braunwald, E.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2021-09-23
Volume
27
Issue
10
Pages
1818-1824
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/s41591-021-01505-4
PMC
PMC8666141
Cited by
139
References
1
Language
en
Licence
Funders
U.S. Department of Health & Human Services | National Institutes of Health (P50HL112349)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. https://app.cochat.ai/papers/10.1038/s41591-021-01505-4
The paper
Ho, C. Y., Day, S. M., Axelsson, A., Russell, M. W., Zahka, K., Lever, H. M., Pereira, A. C., Colan, S. D., Margossian, R., Murphy, A. M., Canter, C., Bach, R. G., Wheeler, M. T., Rossano, J. W., Owens, A. T., Bundgaard, H., Benson, L., Mestroni, L., Taylor, M. R. G., . . . Braunwald, E. (2021). Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01505-4